The TearLab Corp (TEAR) Lowered to Hold at Zacks Investment Research

The TearLab Corp (TEAR) Lowered to Hold at Zacks Investment Research

According to Zacks, “TearLab Corporation is an ophthalmic device company developing and commercializing novel, lab-on-a-chip technologies that enable eye care practitioners to test for highly sensitive and specific biomarkers in tears at the point-of-care. The Company is commercializing a proprietary in vitro diagnostic tear testing platform, the TearLabTM Osmolarity System, which is capable of accurately and rapidly measuring biomarkers in tears at the point-of-care. The TearLabTM System requires nanoliters of tears for testing, potentially reducing collection time and simplifying the tear collection process. TearLab Corporation, formerly known as OccuLogix Inc., is headquartered in San Diego, California. “

Zacks Investment Research lowered shares of TearLab Corp (NASDAQ:TEAR) from a buy rating to a hold rating in a research note issued to investors on Tuesday, May 16th.

A number of other research analysts have also recently weighed in on TEAR. HC Wainwright set a $12.00 price objective on shares of TearLab Corp and gave the stock a buy rating in a research note on Sunday, March 12th. Craig Hallum set a $6.00 price objective on shares of TearLab Corp and gave the stock a buy rating in a research note on Saturday, March 11th. Feltl & Co. cut shares of TearLab Corp from a strong-buy rating to a buy rating and set a $9.00 price objective for the company. in a research note on Saturday, March 11th. Finally, Rodman & Renshaw dropped their price objective on shares of TearLab Corp from $12.00 to $4.00 and set a buy rating for the company in a research note on Tuesday, May 16th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $5.05. TearLab Corp (NASDAQ TEAR) opened at 1.89 on Tuesday. The stock’s 50 day moving average price is $2.18 and its 200 day moving average price is $4.13. The firm’s market capitalization is $10.84 million. TearLab Corp has a one year low of $1.85 and a one year high of $9.00.

In related news, major shareholder Awm Investment Company, Inc. sold 327,674 shares of the firm’s stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $3.20, for a total transaction of $1,048,556.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 11.60% of the stock is currently owned by company insiders. A hedge fund recently raised its stake in TearLab Corp stock. AWM Investment Company Inc. increased its position in shares of TearLab Corp (NASDAQ:TEAR) by 37.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,277,250 shares of the medical research company’s stock after buying an additional 2,000,000 shares during the period. AWM Investment Company Inc. owned 13.76% of TearLab Corp worth $4,730,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 36.09% of the company’s stock.

About TearLab Corp TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:TEAR”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on TearLab Corp (TEAR) For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment